Date: Monday, November 8, 2021
Session Type: Poster Session C
Session Time: 8:30AM-10:30AM
Background/Purpose: Background: Patients with rheumatologic immune-mediated diseases (R-IMID) with Latent tuberculosis infection (LTBI) requiring biologic therapy (BT) are at an increased risk of active tuberculosis (TB). Screening of LTBI with tuberculin skin test (TST) and/or Interferon (IFN)-γ release assays (IGRA) is recommended before starting of BT.
Purpose: In patients with R-IMID previously to BT our aim was to assess a) prevalence of LTBI, b) importance of using a booster test in negative TST and c) to compare TST with the IGRA test.
Methods: Cross-sectional single University Hospital study including all patients diagnosed with R-IMID who underwent a TST and/or IGRA in the last five years (2016-2020).
TST was performed by a subcutaneous injection of 0.1 ml of purified protein derivative (PPD) with a reading after 72 hours. TST was considered positive with an induration of more than 5 mm of diameter. If the first TST was negative, a new TST (Booster) was performed between 1 and 2 weeks after the first TST.
LTBI was diagnosed by a positive IGRA and/or TST and absence of active TB (Chest radiograph). Diagnosis with IGRA vs TST was compared (Cohen’s kappa coefficient).
Results: We included 1117 patients (741 women/376 men), mean age 53±15 years with LTBI. Chest radiograph was normal in most of the patients, only 39 patients (3.5%) presented signs of previous TB infection, mostly granuloma. Total LTBI prevalence was 31.7% (354/1117). LTBI prevalence in different underlying R-IMID ranges from 35% in vasculitis up to 26.5% in conectivopathies (FIGURE).
Booster was positive in 66 patients (7.7%) out of 859 patients with a negative simple TST. Results of TST (+booster) and IGRA tests are shown in TABLE. TST (+booster) was positive in 187 patients (22.9%) out of 817 with a negative or indeterminate IGRA test. IGRA test was positive in 30 (3.8%) out of 793 patients with a negative TST (+booster). Cohen’s Kappa coefficient between TST (+booster) and IGRA, was 0.381.
Conclusion: LTBI is frequent between patients with R-IMID. Booster after negative simple TST may be useful, since it can detect false negatives for LTBI. IGRA and TST(+booster) show a low grade of agreement. Therefore, performing both tests before BT may be recommendable.
To cite this abstract in AMA style:Martinez-Lopez D, Osorio-Chávez J, Álvarez-Reguera C, Portilla V, gonzalez-Gay M, Blanco R. Epidemiology of Latent Tuberculosis Infection in Patients with Rheumatic Immune-mediated Diseases: Single University Study of 1117 Patients [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/epidemiology-of-latent-tuberculosis-infection-in-patients-with-rheumatic-immune-mediated-diseases-single-university-study-of-1117-patients/. Accessed .
« Back to ACR Convergence 2021
ACR Meeting Abstracts - https://acrabstracts.org/abstract/epidemiology-of-latent-tuberculosis-infection-in-patients-with-rheumatic-immune-mediated-diseases-single-university-study-of-1117-patients/